Oak Hill Bio and Chiesi's OHB-607 trial enrols first European subject for BPD prevention
Oak Hill Bio and Chiesi Group have begun a Phase IIb clinical trial for OHB-607 to prevent bronchopulmonary dysplasia in premature infants across Europe.